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TCT-415
Impact of Old Age on Clinical and Angiographic Characteristics of Coronary
Artery Spasm as assessed by Acetylcholine Provocation test
Woong Gil Choi1, Seung Woon Rha2, Byoung Geol Choi2, Amro Elnagar2, Sung Il
Im2, SunWon Kim2, Jin Oh Na2, Seong Woo Han2, Cheol Ung Choi2, Hong Euy Lim2,
Jin Won Kim2, Eung Ju Kim2, Chang Gyu Park2, Hong Seog Seo2, Dong Joo Oh2
1Konkuk University Chungju Hospital, Chungju, Republic of Korea; 2Korea
University Guro Hospital, Seoul, Republic of Korea
Background: Coronary artery spasm (CAS) is one of the important etiological factors
for patients (pts) with chest pain but no coronary artery stenosis. Generally smoking
and other factors were known the clinical risk factors for CAS. However, clinical
aspects related to age on CAS have been seldom investigated and reported. We
investigated whether there is any impact of old age on CAS and as compared with
younger age by intracoronary acetylcholine (Ach) provocation test.
Methods: A total 2954 consecutive pts without significant coronary artery lesion who
underwent Ach provocation test by injecting incremental doses of 20, 50, 100 ug into
the left coronary artery between March 2004 and April 2009 were enrolled. Significant
CAS was defined as focal or diffuse severe transient luminal narrowing (>70%)
with/without chest pain or ST-T change on ECG. the Ach provocation test results and
its associated parameters were compared between the younger pt group (<50 years old,
n=1044 pts, mean age; 41.13 ± 7.4 years) and older pt group (≥50 years old, n=1910
pts, mean age; 62.06 ± 7.44).
Results: Baseline clinical characteristics were similar between the two groups except
that more male (58.3% vs. 42.0%, p<0.001) and smoker (38.9% vs. 24.3%, p<0.001)
in younger patients group whereas more diabetes mellitus (16.3% vs. 6.0%, p<0.001),
dyslipidemia (21.3% vs. 13.1%, p<0.001) and hypertension (54.2% vs. 32.6%,
p<0.001) in older patients group. The rate of positive Ach provocation test was higher
in the older pts group. Further, older pts group showed higher incidence of diffuse and
multi-vessel spasm (Table).
Conclusion: In our study, we found that old age predisposes towards a higher chances
of significant CAS, diffuse and multivessel spasm as assessed with the intracoronary
Ach provocation test. Special care should be emphasized in older age pts present with
vasospastic angina.
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TCT-437
The Mitochondrial Permeability Transition Pore is a Target for
Pharmacological Cardioprotection in Human Hypertrophic Cardiomyopathy
Paul S C Rees1, 4, Sean M Davidson1, Sian E Harding2, Perry M Elliott3, Derek J
Hausenloy1, Derek M Yellon1
1The Hatter Cardiovascular Institute, University College London, London, United
Kingdom; 2The National Heart and Lung Institute, Imperial College London,
London, United Kingdom; 3The Heart Hospital, University College London
Hospitals, London, London, United Kingdom; 4Dorset Heart Centre, Bournemouth,
United Kingdom
Background: The opening of the mitochondrial permeability transition pore (mPTP)
is a critical determinant of ischaemia-reperfusion injury, and the inhibition of its
opening confers powerful cardioprotection. Whether this cardioprotective effect is
present in the setting of hypertrophic cardiomyopathy (HCM) is investigated in this
study.
Methods: Human cardiomyocytes were isolated from left ventricular septal tissue,
harvested from patients undergoing surgical myectomy for obstructive HCM. The cells
were loaded with the fluorescent dye TMRM which localises to the mitochondria and
generates oxidative stress on confocal imaging. This results in mPTP opening indicated
by collapse of the mitochondrial membrane potential. Time taken to induce loss of
mitochondrial membrane potential was used as a measure of mPTP opening sensitivity.
Cells were randomised as follows: (1)DMSO 0.01% vehicle control (N=8/group)
(2)Cells pre-treated with ciclosporin-A (CsA)(0.2μM) for 15 mins (N=7/group)
(3)Cells pre-treated with atorvastatin(25μM)(N=7/group)
Results: In the control group mPTP opening was induced after 188.7±22.7 seconds of
oxidative stress, providing evidence for a functional mPTP in HCM. Furthermore, pre-
treatment with the known mPTP inhibitor, CsA, and atorvastatin, delayed the onset of
mPTP opening by 51±10% (P<0.001) and 35±7% (P<0.05), respectively.
Human cardiomyocyte with wave of depolarisation at left lower edge
Conclusion: For the first time in diseased human ventricular myocytes, we have
demonstrated that the mPTP is functional and that its opening can be inhibited by
cardioprotective agents such as CsA and atorvastatin.
TCT-438
Atorvastatin, Administered at the Onset of Reperfusion, Protects Human
Myocardium Against Lethal Reperfusion Injury by Activation of the RISK
pathway
Paul S C Rees1, 2, Derek J Hausenloy1, Derek M Yellon1
1The Hatter Cardiovascular Institute, University College London, London, United
Kingdom; 2Dorset Heart Centre, Bournemouth, United Kingdom
Background: HMG Co-A reductase inhibitor (statin) therapy has been shown to reduce
peri-procedural event rates and myocardial injury in patients undergoing percutaneous
coronary intervention and cardiac surgery. In experimental animal models, treatment
with statins reduces myocardial infarct size by up-regulating enzymes of the
Reperfusion Injury Salvage Kinase (RISK) pathway. Whether this opportunity for
pharmacological cardioprotection exists in humans is unknown.
Methods: Right atrial appendages were harvested from consenting adult patients
undergoing elective cardiac surgery. From these, individual atrial trabeculae were
explanted. Trabeculae were then suspended in an organ bath and subjected to 90
minutes hypoxia followed by 120 minutes reoxygenation in order to simulate
ischaemia-reperfusion injury (IRI). At the end of the protocol, recovery of contractile
function was determined and compared to baseline. Trabeculae were randomised into
the following groups: Control (N=14); Hypoxic preconditioning (positive control)
(N=4); ATV (25μM) at reoxygenation (N=9); ATV & UO (10μM), an Erk1/2 inhibitor
(N=5); ATV & LY (15μM), a PI3K inhibitor (N=5); ATV & L-NAME (100μM), a non-
specific NOS inhibitor (N=7); ATV & 1400W (5μM), a specific inducible NOS
inhibitor (N=5); Inhibitors and vehicle agents alone had no effect on recovery (N=18).
Results: Trabeculae in the control group recovered 37.5±1.6% of baseline contractile
function following simulated IRI. Treatment with ATV at reperfusion significantly
improved recovery (61.1±3.8%, p<0.001). This effect was abolished by
LY(29.88±2.3%), UO(45.0±3.8%), L-NAME(34.35±4.0%) & 1400W(38.57±5.0%).
Conclusion: Atorvastatin, administered at reoxygenation, protects human atrial
myocardium from simulated ischaemia-reperfusion injury via activation of PI3-K, Erk
1/2 and NOS, components of the RISK pathway.
TCT-439
Peri-adventitial Delivery of a Nanoparticle Albumin-Bound (nab) Rapamycin
Solution Reduces Luminal Stenosis in a Porcine Femoral Artery Balloon Injury
Model
Warren J Gasper1, Cynthia A Jimenez1, Kirk Seward2, Michael S Conte1, Christopher
D Owens1
1University of California, San Francisco, San Francisco, CA; 2Mercator
MedSystems, Inc., San Leandro, CA
Background: Rapamycin-based drug delivery platforms in peripheral arteries have
proven to be safe and feasible but not effective in reducing intimal hyperplasia (IH).
We sought to determine whether periadventitial delivery of rapamycin would be
effective in reducing luminal stenosis in a porcine balloon injury model.
Methods: Femoral artery injury sites were created with a pressure-controlled
endothelial denudation. Two weeks later,a 20-30% overstretch of the injury sites was
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performed. Under fluoroscopy, nab-rapamycin (Abraxis Bioscience) (5 or 500 μg) or
vehicle was delivered to the adventitia using a micro-infusion catheter (Mercator
MedSystems). After 28 days,the arteries were harvested. The primary outcome was
histomorphometric evidence of luminal stenosis and remodeling. Vessel injury was
scored on a validated ordinal scale.
Results: There was 100% procedural success in 16 injury sites treated with adventitial
injections. Nab-rapamycin treated vessels had significantly larger lumen (p=0.01,
ANOVA) and total vessel areas (p=0.005) indicating less negative remodeling. Percent
luminal stenosis and maximal intimal width decreased in a dose-dependent fashion.
Control vessels had significantly more fibrosis (p<0.001).
Mean values for measured and calculated metrics for 16 injured femoral
segments treated with adventitial injection of vehicle or nab-rapamycin
*p-values based on ANOVA
Conclusion: These data suggest that adventitial delivery of rapamycin decreases
luminal stenosis by inhibiting IH and preventing negative remodeling. The decreased
fibrosis in treated vessels suggests a mechanism by which rapamycin may affect vessel
remodeling following injury.
TCT-440
Allogeneic Mesenchymal Precursor Cells Reduce Infarct Size and Preserve
Cardiac Function Following Intracoronary Infusion in a Sheep Model of Acute
Myocardial Infarction
Jaco Houtgraaf1, Renate de Jong1, Kushan Kazemi1, Imo Hoefer2, Gerard
Pasterkamp2, Patrick W Serruys1, Henricus J Duckers1
1Erasmus University Medical Center, Rotterdam, Netherlands; 2University Medical
Center Utrecht, Utrecht, Netherlands
Background: Mesenchymal precursor cells (MPC) are cells that exerted therapeutic
actions in pre-clinical models of acute myocardial infarction (AMI). They are immune
privileged and can be given in an allogeneic setting. The aim of the current large animal
study was to assess the effect of intracoronary delivery of allogeneic MPC directly
following an AMI.
Methods: The 30 sheep that survived the anterior AMI were blindly randomized to
receive IC infusion of either saline (n=10) or three incremental doses of allogeneic
MPC (n=20). Cardiac function was assessed using echocardiography. After 8 weeks,
sheep were sacrificed and the hearts excised for morphometric and histological
analysis.
Results: In the control group, global LVEF deteriorated to 36.6±2.0%, whereas it was
enhanced in treated sheep to 45.4±1.4% (p= 0.009). Also regional function improved,
as fractional area change (FAC) in the apex increased by 39% in MPC-treated animals
compared to controls (p=0.027), and FAC in the mid-ventricle increased by 30%
(p=0.007). Local systolic wall thickening in the affected antero-septal wall improved
from 9.6±5.5% in controls to 39.1±1.8% in treated animals (p< 0.001) and in the
anterior wall from 13.8± 3.6% to 34.7±1.9% (p<0.001). Morphometric analysis
revealed that MPC treatment resulted in a 40% reduction in infarct size from
18.2±1.7% in control animals to only 10.9±0.6% in treated sheep (p<0.001). Also,
infarct (p<0.001) and border zone (p=0.011) thickness were enhanced in the treatment
group. Histological analysis showed an increase in blood vessel density of >50% in
the infarct (p<0.001), remote (p=0.007) and border (p<0.001) areas evoked by MPC
therapy. In addition, cardiomyocyte size was smaller in border (p<0.001) and remote
(p=0.002) areas, accompanied by reduced collagen contents, suggestive of decreased
remodeling.
Conclusion: Intracoronary delivery of allogeneic MPC directly after the AMI resulted
in preserved global and regional cardiac function, evoked by reduced infarct size,
increased perfusion and reduced remodeling.
TCT-441
Peri-adventitial Renal Artery Delivery of Guanethidine Monosulfate Attenuates
Renal Nerve Function: Preclinical Experience and Implication for Resistant
Hypertension
Christopher D Owens1, Warren J Gasper1, Serge Rousselle2, Kirk Seward3
1University of California, San Francisco, San Francisco, CA; 2Alizée Pathology,
Thurmont, MD; 3Mercator MedSystems, Inc., San Leandro, CA
Background: Renal sympathetic nerve hyperactivity contributes to resistant
hypertension. Recent innovation with catheter-based ablation of renal nerves has shown
efficacy in reducing blood pressure without procedural mortality. We hypothesize that
pharmacologic sympathectomy with guanethidine monosulfate (GNT) delivered to
renal peri-adventitial tissue would produce sustained renal artery denervation.
Methods: A micro-infusion catheter (Bullfrog®, Mercator MedSystems, Inc.) was
introduced via femoral artery into renal arteries of (N=15) swine. GNT (50 mg/6 ml,
N=12) or vehicle (6 ml, N=3) was infused to the peri-adventitia of each renal artery
under fluoroscopic guidance. Subjects were divided between a pharmacokinetic (PK)
experiment with 3 treated subjects each sacrificed at 1, 7 or 28 days, and a histology
experiment with 3 treated and 3 control subjects sacrificed at 28 days. The primary
efficacy endpoint for both experiments was kidney NE tissue content. Secondary
outcomes were plasma and tissue GNT levels, histological evidence of renal artery
denervation and renal artery injury.
Results: The 24 treated and 6 control renal arteries had 100% procedural success in
the delivery of GNT or vehicle. Histology showed optimal healing in injected renal
arteries: complete endothelialization, no thrombus formation, no or minimal non-
stenosing neointima and no or minimal medial fibrosis, with no difference between
treated and control arteries (p=NS). There was a time-dependent decrease in renal NE
content, dropping 20±16% (p=NS) by 7 days and 58±10% (p<0.024) at 28 days, each
compared to vehicle controls at 28 days. Denervation was evident from NE drops and
from histology, with reduced fiber density and endo- and peri-neurial fibrosis in GNT-
injected animals, but no neuronal changes evident in vehicle controls. PK analysis
revealed GNT retention of 54 ng/g around the renal arteries at 28 days. By contrast,
GNT plasma concentrations were below adrenergic blocking levels at 24 hours post-
injection.
Conclusion: GNT, delivered to the renal peri-adventitia resulted in a time-dependent
reduction in kidney NE content and specific immune-mediated destruction of renal
artery perivascular nerve tissue. Peri-adventitial drug delivery appears to be a safe and
efficient modality to maximize tissue concentration while minimizing plasma spillover.
TCT-442
The Controlled Reperfusion with Bivalirudin and Intra Coronary Abciximab in
the Porcine Mycoardial Infarction/Reperfusion Model
Piotr P Buszman1, Wojciech Wojakowski1, Krzystof Milewski1, Marcin Debinski1,
Jacek Pajak2, Wanda Jackiewicz1, Michal Jelonek1, Pawel E Buszman1, 2
1Cardiovascular Research adn Development, American Heart of Poland, Katowice,
Poland; 2Medical University of Silesia, Katowice, Poland
Background: The influence of intracoronary abciximab and bivalirudin as an
anticoagulant in ST elevation mycoardial infarction (STEMI) on myocardial salvage
and reperfusion injury (RI) is undetermined
Methods: In 23 landrace pigs STEMI was induced by the occlusion of over – the –
wire (OTW) balloon catheter in the medial left anterior descending artery for 60
minutes. In all animals bivalirudin was administred intravenously. Minutes prior to
reperfusion animals were randomized into the study group (n=11) in which 0,4 mg/kg
downstream i.c. abciximab through the central lumen of the OTW was infused, or to
the control group (n=12), in which 5 ml placebo (0,9% NaCl) was adiministred in the
same way. The control coronary angiography and ventriculography was performed
before ischaemia, 30 minutes and 48 hours after reperfusion. The animals were
sacrificed 2 days after the procedure. The infarct area (IA) and area at risk (AAR) were
marked with tetrazolinum and Evans blue respectively. The primary endpoint was the
percentage of IA in the AAR (IA/AAR%) and the left ventricle (IA/LV%).
Results: The animals in both groups were comparable with regard to sex and weight.
Hearts in the both groups had similar AAR (41,9% vs. 40,5%; p=0,7). The average
infarct size was comparable in the control and the study group as expressed by
IA/AAR% (58,1% vs 57,3%; p=0,8) and IA/LV% (28,5% vs. 26,3% p=0,5). This
corresponded well with peak troponin level (138,8 mg/ml vs. 129,8 mg/ml; p=0,59)
and hsCRP concentration (7822,5 ng/ml vs 8806,5 ng/ml; p=0,38). Furthermore the
left ventricle ejection fraction after 48 hours was also equivalent (32,2 % vs 36,5%;
p=0,21), although the decrease from baseline at 48 hours was significantly lower in
the study group (20.5 vs 29.5%, p=0.02) The enhancement of apoptosis in the AAR
was similar in both groups (16,2 vs. 15,1; p=0,07).The number of hemorrhagic
infarctions confirmed by micro and macroscopic evaluation was higher in the study
group (70% vs. 20%, p=0,05)
Conclusion: Intracoronary abciximiab with peripheral bivalirudin is not superior to
bivalirudin unaided in myocardial salvage caused by reperfusion injury in the model
of porcine ischemia/reperfusion model. This could be caused by higher number of
hemorrhagic infarcts caused by abciximab
TCT-443
Systemic and Local Tissue Pharmacokinetics of Single and Overlapping
NEVO™ Sirolimus-Eluting Stents in the Porcine Coronary Artery Model
Rami Tzafriri2, Yi-Ping Sun1, Sylvester Price1, Campbell Rogers3
1Conor Medsystems, LLC, Fremont, CA; 2CBSET, Inc, Lexington, MA; 3Cordis
Corporation, Bridgewater, NJ
Background: Preclinical safety and pharmacokinetics of the NEVO™ stent, a novel
sirolimus-eluting stent (SES) that uses bioresorbable PLGA and reservoirs (RES
TECHNOLOGY™, Cordis Corporation, NJ), have been evaluated on single stent
implants. As patients often receive multiple single or overlapping (OL) stents, we
examined the influence of overlap and sirolimus dose on the systemic and local tissue
pharmacokinetics of NEVO™ stents.
Methods: Single and OL NEVO™ stents, and OL double dose (2x) NEVO™ stents
(2.5x12 mm) were implanted in non-diseased porcine coronary arteries (n=6–
9/cohort/time point; 100% OL) for 1, 3, 8, 14, 30, or 60 days. Harvested stents, arteries,
myocardium, lung, liver, kidney, and blood (4 hours, 1, 2, 3, 5, 8, 14, 30, and 60 days
post-implant) were analyzed for sirolimus content. Abnormal tissues were evaluated
for histopathology.
Results: There were no early deaths or adverse clinical effects from OL 2x-NEVO™
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